You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》和鉑醫藥(02142.HK)公開超購逾77倍 一手中籤率僅10%
阿思達克 12-09 08:33
和鉑醫藥-B(02142.HK)公布招股結果,計劃發行約1.38億股當中10%為本地公開發售,公開發售錄超購77.54倍,經重新分配後,公開發售股數增至40%。而國際發售初步可供認購的發售股份總數約8倍。

每股發售價定於12.38元,約中間價定價(招股價介乎每股11.7至12.92元),一手1,000股中籤率為10%,抽20手才可穩奪一手。該股將於明日(10日)掛牌上市,由摩根士丹利、美國銀行及中信證券擔任聯席保薦人。

是次招股將引入9個基石投資者,包括Black Rock Funds、HBM Health、高瓴資本、Hudson Bay Capital及Octagon Investments、安瀾資本投資、3W、奧博資本與君聯資本,已認購合共5,761.2萬股發售股份,合共相當於緊隨全球發售完成後公司已發行股本約7.5%。

公司預計,所得款項淨額約為15.99億元,約37%將用於研發核心產品HBM9161及HBM9036;約23%用於開發支柱資產HBM4003、註冊備案及潛在商業化;約15%用於其他候選藥物的研發;約12%用於和鉑抗體平台產生的創新型分子發現及合作項目;約5%用以改進平台技術;餘下約8%為一般營運資金。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account